Opportunity Information: Apply for CDC RFA GH15 1625
Apply for CDC RFA GH15 1625
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Improving Isoniazid Preventive Therapy Penetration through Intensification of Case Findings at the Community Level in Rural South Africa under PEPFAR" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.067 Global AIDS.
- This funding opportunity was created on Mar 13, 2015 and posted on Mar 13, 2015.
- Applicants must submit their applications by Apr 15, 2015 Electronically submitted applications must be submitted no later than 1159 p.m., ET, on the listed application due date.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $317,588.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $317,588.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Philanjalo
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This funding opportunity (CDC RFA GH15-1625) was a CDC discretionary cooperative agreement issued under PEPFAR, focused on a very specific piece of work: conducting data analysis activities needed to complete an evaluation titled "Improving Isoniazid Preventive Therapy Penetration through Intensification of Case Finding at the Community Level in South Africa." In practical terms, the grant was not framed as a broad implementation award to launch new field activities from scratch, but rather as targeted support to analyze existing program and evaluation data connected to efforts in rural South Africa to expand uptake of isoniazid preventive therapy (IPT), a key tuberculosis-prevention intervention for people living with HIV.
The public health rationale behind the opportunity sits at the intersection of HIV and TB control. In high-burden settings such as rural South Africa, tuberculosis remains a leading cause of illness and death among people living with HIV. IPT is an evidence-based preventive therapy that reduces the risk of developing active TB in people who do not have active TB disease, especially among HIV-positive individuals. Even when policies recommend IPT, real-world coverage can lag due to challenges like identifying eligible patients, ruling out active TB, ensuring consistent follow-up, and dealing with documentation and supply issues. The evaluation referenced in the announcement suggests the underlying program strategy emphasized "intensification of case finding at the community level," meaning proactive approaches outside or alongside routine clinic visits to find people with symptoms or risk factors, connect them to services, and improve preventive therapy initiation and completion. The grant’s purpose was to help complete the evaluation by analyzing data to determine how well that strategy improved IPT penetration.
Administratively, the award was offered as a cooperative agreement, which typically means CDC expected to have substantial involvement in the work (for example, collaborating on analytic approaches, ensuring alignment with CDC evaluation standards, and guiding interpretation and use of findings). The opportunity fell under the Health activity category and was tied to CFDA 93.067 (Global AIDS), reflecting its PEPFAR linkage. Only one award was anticipated, and the funding amount was fixed: an estimated total of $317,588, with an award ceiling and floor both listed as $317,588. That structure signals a single, clearly scoped project budget rather than a competitive range of award sizes.
The timeline was tight and clearly defined. The FOA was posted March 13, 2015, with an application due date of April 15, 2015, and it required electronic submission by 11:59 p.m. Eastern Time on the closing date. The archive date was April 22, 2015, indicating the opportunity was time-limited and then closed to new applications. No cost sharing or matching was required, which reduces barriers for applicants and is common for many federal public health cooperative agreements, particularly when the work is specialized and tied to a defined evaluation deliverable.
Eligibility was presented in a narrow way. The announcement lists "Others (see text field entitled Additional Information on Eligibility for clarification)" and then provides an "EligibilityInformation" entry naming "Philanjalo." This indicates the competition may have been limited or intended for a particular organization or partner (for example, a local entity involved in the evaluation, a designated implementing partner, or an organization with access to the needed data). In many cases, evaluations rely on data that are owned, managed, or best interpreted by entities already embedded in the program context, so eligibility restrictions can reflect practical needs like data access, existing partnerships, and continuity of analytic methods.
Because the FOA explicitly emphasizes "data analysis activities for completion of the evaluation," the expected work likely included tasks such as cleaning and managing datasets, linking community and clinic records where possible, conducting statistical analyses to measure changes in IPT uptake or coverage, assessing cascade steps (screening, eligibility determination, initiation, adherence, completion), and interpreting results in light of community case-finding intensity and operational factors. Deliverables for a grant like this commonly include analytic reports, final evaluation findings, and possibly manuscripts or presentations, although the announcement excerpt itself only specifies the broad focus on analysis to complete the evaluation rather than listing required products.
For questions or assistance accessing the full announcement, the listed CDC grants policy contact was Mary Hayes (mmh0@cdc.gov). Overall, the opportunity was a single-award, fixed-budget CDC cooperative agreement under PEPFAR designed to finish an evaluation on improving IPT penetration through community-level intensified case finding in rural South Africa, with the main emphasis placed on rigorous analysis of existing data to generate actionable findings for HIV/TB programming.
Frequently Asked Questions (FAQs)
What is CDC RFA GH15-1625?
CDC RFA GH15-1625 was a CDC discretionary cooperative agreement issued under PEPFAR. It focused on a specific set of data analysis activities needed to complete an evaluation titled: "Improving Isoniazid Preventive Therapy Penetration through Intensification of Case Finding at the Community Level in South Africa."
What was the main purpose of this funding opportunity?
The purpose was to provide targeted support to analyze existing program and evaluation data in order to complete the evaluation and determine how well community-level intensified case finding improved IPT penetration in rural South Africa.
Was this grant intended to fund broad program implementation or new field activities?
No. The opportunity was not framed as a broad implementation award to launch new field activities from scratch. It was framed as targeted support for data analysis tied to a defined evaluation.
What public health issue did the opportunity address?
The opportunity addressed the intersection of HIV and TB control in high-burden settings (specifically rural South Africa), where tuberculosis remains a leading cause of illness and death among people living with HIV. The evaluation focused on improving uptake of isoniazid preventive therapy (IPT), a TB-prevention intervention for people living with HIV who do not have active TB disease.
What is isoniazid preventive therapy (IPT) in the context of this opportunity?
Within this opportunity, IPT is described as an evidence-based preventive therapy that reduces the risk of developing active TB in people who do not have active TB disease, especially among HIV-positive individuals.
What does "IPT penetration" mean in the context of the evaluation?
Based on the description provided, "IPT penetration" refers to how widely IPT was taken up or covered among the intended population (such as eligible people living with HIV) in the program context being evaluated.
What strategy was being evaluated?
The strategy emphasized "intensification of case finding at the community level," meaning proactive approaches outside or alongside routine clinic visits to identify people with symptoms or risk factors, connect them to services, and improve initiation and completion of preventive therapy.
What kind of work was the award expected to support?
The FOA emphasized "data analysis activities for completion of the evaluation." Based on the description provided, the work likely included activities such as cleaning and managing datasets, linking community and clinic records where possible, conducting statistical analyses related to IPT uptake/coverage, assessing cascade steps (screening, eligibility determination, initiation, adherence, completion), and interpreting results in relation to the intensity of community case finding and operational factors.
What funding mechanism was used?
The award was offered as a cooperative agreement.
What does it mean that this was a cooperative agreement?
In this context, a cooperative agreement indicates CDC expected substantial involvement in the work, such as collaborating on analytic approaches, ensuring alignment with CDC evaluation standards, and guiding interpretation and use of findings.
Which program or federal initiative was this opportunity linked to?
The cooperative agreement was issued under PEPFAR and was tied to CFDA 93.067 (Global AIDS).
How many awards were anticipated?
Only one award was anticipated.
What was the total funding amount for the award?
The estimated total funding amount was $317,588, and both the award ceiling and floor were listed as $317,588, indicating a fixed-budget, single-award project.
Was cost sharing or matching required?
No. No cost sharing or matching was required.
When was the FOA posted?
The FOA was posted on March 13, 2015.
What was the application due date and submission deadline time?
The application due date was April 15, 2015, and electronic submission was required by 11:59 p.m. Eastern Time on the closing date.
When was the archive date and what did it indicate?
The archive date was April 22, 2015. This indicated the opportunity was time-limited and then closed to new applications.
What was the activity category for this opportunity?
The opportunity fell under the Health activity category.
Who was eligible to apply?
Eligibility was presented narrowly. The announcement lists "Others (see text field entitled Additional Information on Eligibility for clarification)" and includes an "EligibilityInformation" entry naming "Philanjalo," suggesting the competition may have been limited or intended for a particular organization or partner.
Why might eligibility have been restricted for this opportunity?
Based on the description provided, evaluations often rely on data owned, managed, or best interpreted by entities already embedded in the program context. Eligibility restrictions can reflect practical needs such as data access, existing partnerships, and continuity of analytic methods.
Where was the work focused?
The work was connected to efforts in rural South Africa and to an evaluation centered on community-level case finding to improve IPT uptake.
Was the focus on generating new data or analyzing existing data?
The FOA description emphasizes analyzing existing program and evaluation data to complete the evaluation, rather than generating new data through new field activities.
Were specific deliverables listed in the provided description?
The excerpt provided specifies a broad focus on analysis to complete the evaluation, but it does not list specific required products. It notes that deliverables in grants like this commonly include analytic reports, final evaluation findings, and possibly manuscripts or presentations, but those items are described as common rather than explicitly required in the excerpt.
Who was the CDC grants policy contact for questions or assistance?
The listed CDC grants policy contact was Mary Hayes (mmh0@cdc.gov).
Browse more opportunities from the same category: Health
Next opportunity: SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics and Prognostics Toward Commercialization (R44)
Previous opportunity: NIDDK Research Education Program Grants for Curriculum Development (R25)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA GH15 1625
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA GH15 1625) also looked into and applied for these:
| Funding Opportunity |
|---|
| Reduction of Hemolysis in Specimens from Patients in Emergency Departments Evaluation of Laboratory Medicine Best Practices and Recommendations Apply for CDC RFA OE15 1503 Funding Number: CDC RFA OE15 1503 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| FY15 Announcement of Availability of Funds to Enroll Family Planning Clients into Health Insurance Programs Apply for PA FPH 15 029 Funding Number: PA FPH 15 029 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $200,000 |
| Noncommunicable Disease Prevention and Health Promotion in the Region of the Americas, PAHO Apply for CDC RFA GH15 1618 Funding Number: CDC RFA GH15 1618 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $10,000,000 |
| Targeted Capacity Expansion Substance Use Disorder Treatment for Racial/Ethnic Minority Populations at High Risk for HIV/AIDS (Short Title TCE HIV High Risk Populations) Apply for TI 15 006 Funding Number: TI 15 006 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $500,000 |
| FY15 National Health Education Program on Lupus Apply for MP CPI 15 001 Funding Number: MP CPI 15 001 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $500,000 |
| Health Careers Opportunity Program Apply for HRSA 15 042 Funding Number: HRSA 15 042 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Comparative Physiological Studies of Aging (R03) Apply for RFA AG 16 003 Funding Number: RFA AG 16 003 Agency: National Institutes of Health Category: Health Funding Amount: $50,000 |
| FY15 National Workforce Diversity Pipeline Program Apply for MP CPI 15 002 Funding Number: MP CPI 15 002 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $500,000 |
| Molecular Imaging of the Lung Phase 2 (R01) Apply for RFA HL 16 001 Funding Number: RFA HL 16 001 Agency: National Institutes of Health Category: Health Funding Amount: $450,000 |
| Service Area Competition Additional Area (SAC AA) Cheyenne, WY Apply for HRSA 15 147 Funding Number: HRSA 15 147 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| AHRQ Small Research Grant Program (R03) Apply for PA 15 147 Funding Number: PA 15 147 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $100,000 |
| Tribal Management Grant Program Apply for HHS 2015 IHS TMD 0001 Funding Number: HHS 2015 IHS TMD 0001 Agency: Indian Health Service Category: Health Funding Amount: $100,000 |
| NIMH Research Education Mentoring Programs for HIV/AIDS Researchers (R25) Apply for PAR 15 145 Funding Number: PAR 15 145 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Engaging State and Local Emergency Management Agencies to Improve Ability to Prepare for and Respond to All Hazards Events Apply for CDC RFA TP13 130103CONT15 Funding Number: CDC RFA TP13 130103CONT15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| The Role of Exosomes in HIV Neuropathogenesis (R01) Apply for RFA MH 16 100 Funding Number: RFA MH 16 100 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| FY15 Partnerships to Increase Coverage in Communities II Initiative Apply for MP CPI 15 003 Funding Number: MP CPI 15 003 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $250,000 |
| National Ebola Training and Education Center (NETEC) Apply for EP U3R 15 003 Funding Number: EP U3R 15 003 Agency: Assistant Secretary for Preparedness and Response Category: Health Funding Amount: $12,000,000 |
| Improving the Health of People with Intellectual Disabilities Apply for CDC RFA DD12 12010101SUPP15 Funding Number: CDC RFA DD12 12010101SUPP15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,667,000 |
| The Role of Exosomes in HIV Neuropathogenesis (R21) Apply for RFA MH 16 110 Funding Number: RFA MH 16 110 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Sudden Unexpected Infant Death (SUID) Case Registry Building Capacity (Module A) and Implementation (Module B) Apply for CDC RFA DP15 1506 Funding Number: CDC RFA DP15 1506 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $118,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA GH15 1625", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.